Canada-wide Implementation of a Virtual Sexual Health and Rehabilitation eClinic (SHAReClinic) for Prostate Cancer Patients and Their Partners

What this study is about

The goal of this observational study is to evaluate the effectiveness of SHAReClinic, a national, virtual Sexual Health and Rehabilitation eClinic designed to support prostate cancer patients and their partners. Specifically, this study aims to assess SHAReClinic's impact on improving sexual function, satisfaction, and relational intimacy after treatment. The primary objective is to evaluate SHAReClinic's effectiveness across participating sites and determine its role in supporting long-term sexual health and well-being. As part of usual care, newly enrolled SHAReClinic patients will receive guided education modules and access to sexual health counselling at key recovery milestones. SHAReClinic seeks to expand access to sexual health care for prostate cancer patients across Canada by providing evidence-based, virtual sexual rehabilitation. Findings from this study will inform best practices in survivorship care and contribute to the development of a national standard for oncology sexual health interventions.

Who can join (things the study team will check)

✅ You may be able to join if…

• Patients who are scheduled for first-line treatment for localized prostate cancer, either through radical prostatectomy (open or robotic) or radiation treatment (brachytherapy, external beam) Alone, or with adjuvant Androgen Deprivation Therapy (ADT) OR
  • Patients currently undergoing active treatment for prostate cancer OR
  • Patients who have undergone cancer treatment in the past 6 months
  • Patients who are hormone and/or chemotherapy-naïve
  • Patients who have access to a computer or smartphone with internet access
  • Patients who are 18 years of age or older

🚫 You may not be able to join if…

• Patients on ADT alone as primary treatment, and/or patients on chemotherapy
• Patients who lack English proficiency
• Patients on nitrate therapy or have other contra-indications to phosphodiesterase type 5 inhibitors (PDE5i's)
• Patients with medical conditions that would preclude safe sexual activity
• Patients who have had previous treatment for PCa

Where this trial is running

• Vancouver Coastal Health Authority, Vancouver, British Columbia, Canada
• Men's Health Clinic Manitoba, Winnipeg, Manitoba, Canada
• Royal Victoria Regional Health Centre, Barrie, Ontario, Canada
• Dianne & Irving Kipnes Urology Centre, Edmonton, Ontario, Canada
• Kingston Health Sciences Centre, Kingston, Ontario, Canada
• St. Joseph's Health Care London, London, Ontario, Canada
• Trillium Health Partners, Mississauga, Ontario, Canada
• Grass Family Men's Health Center, Ottawa, Ontario, Canada
• University Health Network, Toronto, Ontario, Canada
• St. Paul's Hospital, Saskatoon, Saskatchewan, Canada

Who to contact

Steven Guirguis, MA · 416-946-4501 · steven.guirguis@uhn.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06877598.